Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10110041 | Papillomavirus Research | 2018 | 24 Pages |
Abstract
The qHPV vaccine elicits durable titer response above the seroconversion cut-off levels in HIV-infected women. However, the titer levels were substantially lower by Week 72, most noticeably in type 18. HPV DNA was detected more frequently in the anal canal. Detection of non-vaccine high risk HPV suggests a role for the nonavalent vaccine.
Keywords
quadrivalent HPV vaccineqHPVNIDCRACTGNIAIDAmCGMTFDAMMUNIHDNACervical intraepithelial neoplasiaAnogenitaldeoxyribonucleic acidImmunogenicityCinAntiretroviral therapyWomenFood and Drug AdministrationVINconfidence intervalNational Institutes of HealthNational Institute of Allergy and Infectious DiseasesNational Institute of Dental and Craniofacial Researchgeometric mean titersVaginal intraepithelial neoplasiaARTQuadrivalent human papillomavirus vaccinepolymerase chain reactionPCRhuman immunodeficiency virusHIVHuman papillomavirusHPVAIDS Clinical Trials Group
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Michelle S. Cespedes, Minhee Kang, Erna Milunka Kojic, Triin Umbleja, Catherine Godfrey, Jennifer Y. Webster-Cyriaque, Reena Masih, Cynthia Firnhaber, Beatriz Grinsztejn, Alfred Saah, Susan Cu-Uvin, Judith A. Aberg,